首页 > 最新文献

Endocrinology and Metabolism最新文献

英文 中文
Long-Term Antithyroid Drug Therapy in Smoldering or Fluctuating-Type Graves' Hyperthyroidism with Potassium Iodide. 用碘化钾长期抗甲状腺药物治疗燃烧型或波动型巴塞杜氏甲状腺功能亢进症
IF 3.9 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-16 DOI: 10.3803/EnM.2024.2079
Ken Okamura

Graves' hyperthyroidism is characterized by stimulation of the thyroid gland by thyroid-stimulating hormone receptor antibodies (TRAbs). Antithyroid drug (ATD) continuation is recommended as long as the thyroid gland is stimulated. Goiter size, thyroidal 123I uptake, serum thyroglobulin level, and TRAb positivity are reliable markers of thyroid stimulation. Attention must also be paid to the responsiveness of the thyroid gland due to the high prevalence of painless thyroiditis and spontaneous hypothyroidism during treatment. TRAbs disappeared at <5 years entering remission in 36.6% of patients (smooth-type), while re-elevation of TRAb activity occurred in 37.7% (fluctuating-type) and remained positive for >5 years in 21.1% (smoldering-type). Seven percent of patients remained positive for TRAbs for >30 years, requiring life-long ATD treatment. Remission occurred after median 6.8 years (interquartile range, 4.0 to 10.9) of ATD treatment in 55% of patients. However, late relapse may occur after stressful events (dormant type). In apparently intractable Graves' disease (GD) with a large goiter (>40 g), 131I therapy should be considered. For initial and long-term ATD treatment, we must choose effective, safe, and economical drugs such as 100 mg potassium iodide (KI), although KI sensitivity varies in patients with GD. Thionamide, which has notorious side effects, is added only during the KI-resistant period.

巴塞杜氏甲状腺功能亢进症的特点是甲状腺受到促甲状腺激素受体抗体(TRAbs)的刺激。只要甲状腺受到刺激,就建议继续服用抗甲状腺药物(ATD)。甲状腺肿大、甲状腺 123I 摄取、血清甲状腺球蛋白水平和 TRAb 阳性是甲状腺刺激的可靠标志。由于治疗期间无痛性甲状腺炎和自发性甲状腺功能减退症的发病率很高,因此还必须注意甲状腺的反应性。21.1%的患者(烟熏型)在5年后TRAbs消失。7%的患者在超过30年的时间里TRAbs仍呈阳性,需要终生接受ATD治疗。55%的患者在接受 ATD 治疗中位数为 6.8 年(四分位数间距为 4.0 至 10.9)后病情得到缓解。然而,晚期复发也可能发生在应激事件之后(休眠型)。对于甲状腺肿大(大于40克)且明显难治的巴塞杜氏病(GD)患者,应考虑采用131I治疗。对于初始和长期的ATD治疗,我们必须选择有效、安全和经济的药物,如100毫克碘化钾(KI),尽管GD患者对KI的敏感性各不相同。只有在 KI 耐药期才会添加副作用显著的硫酰胺。
{"title":"Long-Term Antithyroid Drug Therapy in Smoldering or Fluctuating-Type Graves' Hyperthyroidism with Potassium Iodide.","authors":"Ken Okamura","doi":"10.3803/EnM.2024.2079","DOIUrl":"https://doi.org/10.3803/EnM.2024.2079","url":null,"abstract":"<p><p>Graves' hyperthyroidism is characterized by stimulation of the thyroid gland by thyroid-stimulating hormone receptor antibodies (TRAbs). Antithyroid drug (ATD) continuation is recommended as long as the thyroid gland is stimulated. Goiter size, thyroidal 123I uptake, serum thyroglobulin level, and TRAb positivity are reliable markers of thyroid stimulation. Attention must also be paid to the responsiveness of the thyroid gland due to the high prevalence of painless thyroiditis and spontaneous hypothyroidism during treatment. TRAbs disappeared at <5 years entering remission in 36.6% of patients (smooth-type), while re-elevation of TRAb activity occurred in 37.7% (fluctuating-type) and remained positive for >5 years in 21.1% (smoldering-type). Seven percent of patients remained positive for TRAbs for >30 years, requiring life-long ATD treatment. Remission occurred after median 6.8 years (interquartile range, 4.0 to 10.9) of ATD treatment in 55% of patients. However, late relapse may occur after stressful events (dormant type). In apparently intractable Graves' disease (GD) with a large goiter (>40 g), 131I therapy should be considered. For initial and long-term ATD treatment, we must choose effective, safe, and economical drugs such as 100 mg potassium iodide (KI), although KI sensitivity varies in patients with GD. Thionamide, which has notorious side effects, is added only during the KI-resistant period.</p>","PeriodicalId":11636,"journal":{"name":"Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elucidating Clinical Queries for Tailored Therapy in Patients with Prolactinoma. 阐明临床问题,为泌乳素瘤患者量身定制治疗方案
IF 3.9 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-14 DOI: 10.3803/EnM.2024.2057
Min-Ho Lee, Jae Won Hong, Kyungwon Kim, Cheol Ryong Ku, Eun Jig Lee

Prolactinomas are the most prevalent type of pituitary neuroendocrine adenomas, primarily affecting women of reproductive age. Unlike other pituitary tumors, the first-line management has traditionally been pharmacological rather than surgical. This preference is due to the effectiveness of dopamine agonists (DAs), which typically reduce tumor size and normalize prolactin levels in most patients. However, this does not imply that there is no room for improvement; the duration of treatment and medication side effects often lead to compliance issues among patients. Recent advances in surgical techniques and molecular biology have paved the way for the development of precision medicine, allowing for more flexible and personalized treatment strategies for prolactinomas. This review aims to enhance clinical decision-making and patient care for endocrinologists by focusing on several key factors: predictive markers of DA sensitivity, clinical characteristics and suitability for transsphenoidal adenomectomy as a potential first-line treatment, factors determining the successful withdrawal of DAs after prolonged use, safety concerns during pre/post-pregnancy and breastfeeding, and determinants of tumor aggressiveness. Through tailored therapy-a patient-focused, multidisciplinary approach- we aim to improve the management of prolactinoma patients.

催乳素瘤是垂体神经内分泌腺瘤中最常见的一种,主要影响育龄妇女。与其他垂体瘤不同,传统的一线治疗方法是药物治疗而非手术治疗。之所以选择药物治疗,是因为多巴胺激动剂(DAs)疗效显著,通常能缩小肿瘤体积,并使大多数患者的泌乳素水平恢复正常。然而,这并不意味着没有改进的余地;治疗的持续时间和药物副作用常常导致患者的依从性问题。外科技术和分子生物学的最新进展为精准医疗的发展铺平了道路,使催乳素瘤的治疗策略更加灵活和个性化。本综述旨在通过关注以下几个关键因素,加强内分泌专家的临床决策和患者护理:泌乳素瘤敏感性的预测指标、经蝶鞍腺瘤切除术作为潜在一线治疗的临床特征和适宜性、长期使用泌乳素瘤药物后成功停药的决定因素、孕前/孕后和哺乳期的安全问题以及肿瘤侵袭性的决定因素。通过量身定制的疗法--以患者为中心的多学科方法--我们旨在改善催乳素瘤患者的治疗。
{"title":"Elucidating Clinical Queries for Tailored Therapy in Patients with Prolactinoma.","authors":"Min-Ho Lee, Jae Won Hong, Kyungwon Kim, Cheol Ryong Ku, Eun Jig Lee","doi":"10.3803/EnM.2024.2057","DOIUrl":"https://doi.org/10.3803/EnM.2024.2057","url":null,"abstract":"<p><p>Prolactinomas are the most prevalent type of pituitary neuroendocrine adenomas, primarily affecting women of reproductive age. Unlike other pituitary tumors, the first-line management has traditionally been pharmacological rather than surgical. This preference is due to the effectiveness of dopamine agonists (DAs), which typically reduce tumor size and normalize prolactin levels in most patients. However, this does not imply that there is no room for improvement; the duration of treatment and medication side effects often lead to compliance issues among patients. Recent advances in surgical techniques and molecular biology have paved the way for the development of precision medicine, allowing for more flexible and personalized treatment strategies for prolactinomas. This review aims to enhance clinical decision-making and patient care for endocrinologists by focusing on several key factors: predictive markers of DA sensitivity, clinical characteristics and suitability for transsphenoidal adenomectomy as a potential first-line treatment, factors determining the successful withdrawal of DAs after prolonged use, safety concerns during pre/post-pregnancy and breastfeeding, and determinants of tumor aggressiveness. Through tailored therapy-a patient-focused, multidisciplinary approach- we aim to improve the management of prolactinoma patients.</p>","PeriodicalId":11636,"journal":{"name":"Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thyroid Hormone-Mediated Selective Autophagy and Its Implications in Countering Metabolic Dysfunction-Associated Steatotic Liver Disease. 甲状腺激素介导的选择性自噬及其在对抗代谢功能障碍相关性脂肪肝中的意义
IF 3.9 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-01 Epub Date: 2024-10-14 DOI: 10.3803/EnM.2024.2068
Rohit A Sinha

The influence of thyroid hormone (TH) on liver metabolism has attracted the attention of pharmacologists seeking new treatments for metabolic dysfunction-associated steatotic liver disease (MASLD), an increasingly common metabolic disorder. In this context, the selective induction of autophagy by TH in preclinical models has been identified as a promising mechanism. In this process, TH clears intrahepatic fat through lipophagy while protecting against inflammation and mitochondrial damage in hepatocytes via mitophagy. Furthermore, TH-induced aggrephagy may represent a protective mechanism to mitigate the development of MASLD-associated hepatocellular carcinoma. Considering the defects in autophagy observed during the progression of human MASLD, the induction of autophagy by TH, its metabolites, and its analogs represent a novel strategy to combat hepatic damage across the MASLD spectrum.

甲状腺激素(TH)对肝脏代谢的影响引起了药理学家的关注,他们正在寻找治疗代谢功能障碍相关性脂肪性肝病(MASLD)的新方法,这是一种越来越常见的代谢性疾病。在这种情况下,临床前模型中 TH 对自噬的选择性诱导被认为是一种很有前景的机制。在这一过程中,TH 通过脂肪吞噬清除肝内脂肪,同时通过有丝分裂保护肝细胞免受炎症和线粒体损伤。此外,TH 诱导的自噬可能是一种保护机制,可减轻 MASLD 相关肝细胞癌的发展。考虑到在人类 MASLD 进展过程中观察到的自噬缺陷,TH、其代谢物及其类似物诱导自噬是对抗整个 MASLD 肝损伤的一种新策略。
{"title":"Thyroid Hormone-Mediated Selective Autophagy and Its Implications in Countering Metabolic Dysfunction-Associated Steatotic Liver Disease.","authors":"Rohit A Sinha","doi":"10.3803/EnM.2024.2068","DOIUrl":"10.3803/EnM.2024.2068","url":null,"abstract":"<p><p>The influence of thyroid hormone (TH) on liver metabolism has attracted the attention of pharmacologists seeking new treatments for metabolic dysfunction-associated steatotic liver disease (MASLD), an increasingly common metabolic disorder. In this context, the selective induction of autophagy by TH in preclinical models has been identified as a promising mechanism. In this process, TH clears intrahepatic fat through lipophagy while protecting against inflammation and mitochondrial damage in hepatocytes via mitophagy. Furthermore, TH-induced aggrephagy may represent a protective mechanism to mitigate the development of MASLD-associated hepatocellular carcinoma. Considering the defects in autophagy observed during the progression of human MASLD, the induction of autophagy by TH, its metabolites, and its analogs represent a novel strategy to combat hepatic damage across the MASLD spectrum.</p>","PeriodicalId":11636,"journal":{"name":"Endocrinology and Metabolism","volume":" ","pages":"686-692"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Diabetes on COVID-19 Susceptibility: A Nationwide Propensity Score Matching Study. 糖尿病对 COVID-19 易感性的影响:全国倾向得分匹配研究》。
IF 3.9 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-01 Epub Date: 2024-08-28 DOI: 10.3803/EnM.2024.2014
Han Na Jang, Sun Joon Moon, Jin Hyung Jung, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee

Prior research has highlighted poor clinical outcomes in coronavirus disease 2019 (COVID-19)-infected patients with diabetes; however, susceptibility to COVID-19 infection in patients with diabetes has not been extensively studied. Participants aged ≥30 years who underwent COVID-19 testing from December 2019 to April 2020 were analyzed using the National Health Insurance Service data in South Korea. In a cohort comprising 29,433 1:1 propensity score-matched participants, COVID-19 positivity was significantly higher in participants with diabetes than in those without diabetes (512 [3.5%] vs. 395 [2.7%], P<0.001). Logistic regression analysis indicated that diabetes significantly increased the risk of COVID-19 test positivity (odds ratio, 1.307; 95% confidence interval, 1.144 to 1.493; P<0.001). Patients with diabetes exhibited heightened COVID-19 infection rates compared to individuals without diabetes, and diabetes increased the susceptibility to COVID-19, reinforcing the need for heightened preventive measures, particularly considering the poor clinical outcomes in this group.

先前的研究强调,感染冠状病毒病2019(COVID-19)的糖尿病患者临床疗效不佳;然而,糖尿病患者对COVID-19感染的易感性尚未得到广泛研究。我们利用韩国国民健康保险服务数据分析了在2019年12月至2020年4月期间接受COVID-19检测的年龄≥30岁的参与者。在由 29,433 名 1:1 倾向得分匹配参与者组成的队列中,糖尿病患者的 COVID-19 阳性率明显高于非糖尿病患者(512 [3.5%] vs. 395 [2.7%],P
{"title":"Impact of Diabetes on COVID-19 Susceptibility: A Nationwide Propensity Score Matching Study.","authors":"Han Na Jang, Sun Joon Moon, Jin Hyung Jung, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee","doi":"10.3803/EnM.2024.2014","DOIUrl":"10.3803/EnM.2024.2014","url":null,"abstract":"<p><p>Prior research has highlighted poor clinical outcomes in coronavirus disease 2019 (COVID-19)-infected patients with diabetes; however, susceptibility to COVID-19 infection in patients with diabetes has not been extensively studied. Participants aged ≥30 years who underwent COVID-19 testing from December 2019 to April 2020 were analyzed using the National Health Insurance Service data in South Korea. In a cohort comprising 29,433 1:1 propensity score-matched participants, COVID-19 positivity was significantly higher in participants with diabetes than in those without diabetes (512 [3.5%] vs. 395 [2.7%], P<0.001). Logistic regression analysis indicated that diabetes significantly increased the risk of COVID-19 test positivity (odds ratio, 1.307; 95% confidence interval, 1.144 to 1.493; P<0.001). Patients with diabetes exhibited heightened COVID-19 infection rates compared to individuals without diabetes, and diabetes increased the susceptibility to COVID-19, reinforcing the need for heightened preventive measures, particularly considering the poor clinical outcomes in this group.</p>","PeriodicalId":11636,"journal":{"name":"Endocrinology and Metabolism","volume":" ","pages":"813-818"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Modified S-GRAS Scoring System for Prognosis in Korean with Adrenocortical Carcinoma. 韩国肾上腺皮质癌患者预后的改良 S-GRAS 评分系统
IF 3.9 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-01 Epub Date: 2024-09-25 DOI: 10.3803/EnM.2024.2086
Sun Kyung Baek, Seung Hun Lee, Seung Shin Park, Chang Ho Ahn, Sung Hye Kong, Won Woong Kim, Yu-Mi Lee, Su Jin Kim, Dong Eun Song, Tae-Yon Sung, Kyu Eun Lee, Jung Hee Kim, Kyeong Cheon Jung, Jung-Min Koh

Backgruound: Adrenocortical carcinomas (ACCs) are rare tumors with aggressive but varied prognosis. Stage, Grade, Resection status, Age, Symptoms (S-GRAS) score, based on clinical and pathological factors, was found to best stratify the prognosis of European ACC patients. This study assessed the prognostic performance of modified S-GRAS (mS-GRAS) scores including modified grade (mG) by integrating mitotic counts into the Ki67 index (original grade), in Korean ACC patients.

Methods: Patients who underwent surgery for ACC between January 1996 and December 2022 at three medical centers in Korea were retrospectively analyzed. mS-GRAS scores were calculated based on tumor stage, mG (Ki67 index or mitotic counts), resection status, age, and symptoms. Patients were divided into four groups (0-1, 2-3, 4-5, and 6-9 points) based on total mS-GRAS score. The associations of each variable and mS-GRAS score with recurrence and survival were evaluated using Cox regression analysis, Harrell's concordance index (C-index), and the Kaplan-Meier method.

Results: Data on mS-GRAS components were available for 114 of the 153 patients who underwent surgery for ACC. These 114 patients had recurrence and death rates of 61.4% and 48.2%, respectively. mS-GRAS score was a significantly better predictor of recurrence (C-index=0.829) and death (C-index=0.747) than each component (P<0.05), except for resection status. mS-GRAS scores correlated with shorter progression-free survival (P=8.34E-24) and overall survival (P=2.72E-13).

Conclusion: mS-GRAS scores showed better prognostic performance than tumor stage and grade in Asian patients who underwent surgery for ACC.

背景:肾上腺皮质癌(ACC)是一种罕见肿瘤,具有侵袭性,但预后各异。研究发现,基于临床和病理因素的分期、分级、切除状态、年龄、症状(S-GRAS)评分可对欧洲 ACC 患者的预后进行最佳分层。本研究评估了韩国 ACC 患者的改良 S-GRAS 评分(mS-GRAS)的预后效果,包括通过将有丝分裂计数纳入 Ki67 指数(原始分级)而得出的改良分级(mG):根据肿瘤分期、mG(Ki67指数或有丝分裂计数)、切除情况、年龄和症状计算mS-GRAS评分。根据 mS-GRAS 总分将患者分为四组(0-1 分、2-3 分、4-5 分和 6-9 分)。采用 Cox 回归分析、Harrell 一致指数(C-index)和 Kaplan-Meier 法评估了各变量和 mS-GRAS 评分与复发和生存的关系:在153名接受ACC手术的患者中,有114名患者的mS-GRAS成分数据可用。mS-GRAS评分对复发(C-index=0.829)和死亡(C-index=0.747)的预测效果明显优于各组成部分(PC结论:在接受ACC手术的亚洲患者中,mS-GRAS评分的预后效果优于肿瘤分期和分级。
{"title":"The Modified S-GRAS Scoring System for Prognosis in Korean with Adrenocortical Carcinoma.","authors":"Sun Kyung Baek, Seung Hun Lee, Seung Shin Park, Chang Ho Ahn, Sung Hye Kong, Won Woong Kim, Yu-Mi Lee, Su Jin Kim, Dong Eun Song, Tae-Yon Sung, Kyu Eun Lee, Jung Hee Kim, Kyeong Cheon Jung, Jung-Min Koh","doi":"10.3803/EnM.2024.2086","DOIUrl":"10.3803/EnM.2024.2086","url":null,"abstract":"<p><strong>Backgruound: </strong>Adrenocortical carcinomas (ACCs) are rare tumors with aggressive but varied prognosis. Stage, Grade, Resection status, Age, Symptoms (S-GRAS) score, based on clinical and pathological factors, was found to best stratify the prognosis of European ACC patients. This study assessed the prognostic performance of modified S-GRAS (mS-GRAS) scores including modified grade (mG) by integrating mitotic counts into the Ki67 index (original grade), in Korean ACC patients.</p><p><strong>Methods: </strong>Patients who underwent surgery for ACC between January 1996 and December 2022 at three medical centers in Korea were retrospectively analyzed. mS-GRAS scores were calculated based on tumor stage, mG (Ki67 index or mitotic counts), resection status, age, and symptoms. Patients were divided into four groups (0-1, 2-3, 4-5, and 6-9 points) based on total mS-GRAS score. The associations of each variable and mS-GRAS score with recurrence and survival were evaluated using Cox regression analysis, Harrell's concordance index (C-index), and the Kaplan-Meier method.</p><p><strong>Results: </strong>Data on mS-GRAS components were available for 114 of the 153 patients who underwent surgery for ACC. These 114 patients had recurrence and death rates of 61.4% and 48.2%, respectively. mS-GRAS score was a significantly better predictor of recurrence (C-index=0.829) and death (C-index=0.747) than each component (P<0.05), except for resection status. mS-GRAS scores correlated with shorter progression-free survival (P=8.34E-24) and overall survival (P=2.72E-13).</p><p><strong>Conclusion: </strong>mS-GRAS scores showed better prognostic performance than tumor stage and grade in Asian patients who underwent surgery for ACC.</p>","PeriodicalId":11636,"journal":{"name":"Endocrinology and Metabolism","volume":" ","pages":"803-812"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In Vitro Investigation of HIF-1α as a Therapeutic Target for Thyroid-Associated Ophthalmopathy. 将 HIF-1α 作为甲状腺相关眼病治疗靶点的体外研究
IF 3.9 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-01 Epub Date: 2024-10-16 DOI: 10.3803/EnM.2024.1952
Jeongmin Lee, Jinsoo Lee, Hansang Baek, Dong-Jun Lim, Seong-Beom Lee, Jung-Min Lee, Sang-Ah Jang, Moo Il Kang, Suk-Woo Yang, Min-Hee Kim

Backgruound: Thyroid-associated ophthalmopathy (TAO) involves tissue expansion and inflammation, potentially causing a hypoxic microenvironment. Hypoxia-inducible factor (HIF)-1α is crucial in fibrosis and adipogenesis, which are observed in TAO progression. We investigated the effects of hypoxia on orbital fibroblasts (OFs) in TAO, focusing on the role of HIF-1α in TAO progression.

Methods: OFs were isolated from TAO and non-TAO patients (as controls). In addition to HIF-1α, adipogenic differentiation markers including peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer binding protein (CEBP) were measured by Western blot, and phenotype changes were evaluated by Oil Red O staining under both normoxia and hypoxia. To elucidate the effect of HIF-1α inhibition, protein expression changes after HIF-1α inhibitor treatment were evaluated under normoxia and hypoxia.

Results: TAO OFs exhibited significantly higher HIF-1α expression than non-TAO OFs, and the difference was more distinct under hypoxia than under normoxia. Oil Red O staining showed that adipogenic differentiation of TAO OFs was prominent under hypoxia. Hypoxic conditions increased the expression of adipogenic markers, namely PPARγ and CEBP, as well as HIF-1α in TAO OFs. Interleukin 6 levels also increased in response to hypoxia. The effect of hypoxia on adipogenesis was reduced at the protein level after HIF-1α inhibitor treatment, and this inhibitory effect was sustained even with IGF-1 stimulation in addition to hypoxia.

Conclusion: Hypoxia induces tissue remodeling in TAO by stimulating adipogenesis through HIF-1α activation. These data could provide insights into new treatment strategies and the mechanisms of adipose tissue remodeling in TAO.

背景:甲状腺相关性眼病(TAO甲状腺相关性眼病(TAO)涉及组织扩张和炎症,可能导致缺氧微环境。缺氧诱导因子(HIF)-1α在纤维化和脂肪生成过程中起着关键作用,而这在TAO进展过程中也可观察到。我们研究了低氧对TAO眼眶成纤维细胞(OFs)的影响,重点关注HIF-1α在TAO进展中的作用:方法:从TAO患者和非TAO患者(对照组)中分离眼眶成纤维细胞。方法:从TAO和非TAO患者(作为对照组)中分离出OFs,除HIF-1α外,还通过Western印迹法测定了过氧化物酶体增殖激活受体γ(PPARγ)和CCAAT/增强子结合蛋白(CEBP)等成脂分化标记物,并通过油红O染色法评估了正常缺氧和低氧条件下OFs的表型变化。为了阐明抑制HIF-1α的效果,在正常氧和缺氧条件下评估了HIF-1α抑制剂处理后蛋白质表达的变化:结果:TAO OFs的HIF-1α表达量明显高于非TAO OFs,在缺氧条件下的差异比在正常缺氧条件下更明显。油红 O 染色显示,缺氧条件下 TAO OFs 的成脂分化明显。缺氧条件下,TAO OFs 中的成脂标志物(即 PPARγ 和 CEBP)以及 HIF-1α 的表达增加。白细胞介素6水平也随缺氧而增加。经HIF-1α抑制剂处理后,缺氧对脂肪生成的影响在蛋白水平上减弱,即使在缺氧的同时刺激IGF-1,这种抑制作用仍能持续:结论:缺氧通过激活HIF-1α刺激脂肪生成,诱导TAO组织重塑。这些数据可为新的治疗策略和TAO脂肪组织重塑的机制提供启示。
{"title":"In Vitro Investigation of HIF-1α as a Therapeutic Target for Thyroid-Associated Ophthalmopathy.","authors":"Jeongmin Lee, Jinsoo Lee, Hansang Baek, Dong-Jun Lim, Seong-Beom Lee, Jung-Min Lee, Sang-Ah Jang, Moo Il Kang, Suk-Woo Yang, Min-Hee Kim","doi":"10.3803/EnM.2024.1952","DOIUrl":"10.3803/EnM.2024.1952","url":null,"abstract":"<p><strong>Backgruound: </strong>Thyroid-associated ophthalmopathy (TAO) involves tissue expansion and inflammation, potentially causing a hypoxic microenvironment. Hypoxia-inducible factor (HIF)-1α is crucial in fibrosis and adipogenesis, which are observed in TAO progression. We investigated the effects of hypoxia on orbital fibroblasts (OFs) in TAO, focusing on the role of HIF-1α in TAO progression.</p><p><strong>Methods: </strong>OFs were isolated from TAO and non-TAO patients (as controls). In addition to HIF-1α, adipogenic differentiation markers including peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer binding protein (CEBP) were measured by Western blot, and phenotype changes were evaluated by Oil Red O staining under both normoxia and hypoxia. To elucidate the effect of HIF-1α inhibition, protein expression changes after HIF-1α inhibitor treatment were evaluated under normoxia and hypoxia.</p><p><strong>Results: </strong>TAO OFs exhibited significantly higher HIF-1α expression than non-TAO OFs, and the difference was more distinct under hypoxia than under normoxia. Oil Red O staining showed that adipogenic differentiation of TAO OFs was prominent under hypoxia. Hypoxic conditions increased the expression of adipogenic markers, namely PPARγ and CEBP, as well as HIF-1α in TAO OFs. Interleukin 6 levels also increased in response to hypoxia. The effect of hypoxia on adipogenesis was reduced at the protein level after HIF-1α inhibitor treatment, and this inhibitory effect was sustained even with IGF-1 stimulation in addition to hypoxia.</p><p><strong>Conclusion: </strong>Hypoxia induces tissue remodeling in TAO by stimulating adipogenesis through HIF-1α activation. These data could provide insights into new treatment strategies and the mechanisms of adipose tissue remodeling in TAO.</p>","PeriodicalId":11636,"journal":{"name":"Endocrinology and Metabolism","volume":" ","pages":"767-776"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes in the Epidemiological Landscape of Diabetes in South Korea: Trends in Prevalence, Incidence, and Healthcare Expenditures. 韩国糖尿病流行病学的变化:流行率、发病率和医疗支出的趋势。
IF 3.9 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-01 Epub Date: 2024-09-25 DOI: 10.3803/EnM.2024.2073
Kyoung Hwa Ha, Dae Jung Kim

Diabetes is a serious public health concern that significantly contributes to the global burden of disease. In Korea, the prevalence of diabetes is 12.5% among individuals aged 19 and older, and 14.8% among individuals aged 30 and older as of 2022. The total number of people with diabetes among those aged 19 and older is estimated to be 5.4 million. The incidence of diabetes decreased from 8.1 per 1,000 persons in 2006 to 6.3 per 1,000 persons in 2014, before rising again to 7.5 per 1,000 persons in 2019. Meanwhile, the incidence of type 1 diabetes increased significantly, from 1.1 per 100,000 persons in 1995 to 4.8 per 100,000 persons in 2016, with the prevalence reaching 41.0 per 100,000 persons in 2017. Additionally, the prevalence of gestational diabetes saw a substantial rise from 4.1% in 2007 to 22.3% in 2023. These changes have resulted in increases in the total medical costs for diabetes, covering both outpatient and inpatient services. Therefore, effective diabetes prevention strategies are urgently needed.

糖尿病是一个严重的公共卫生问题,极大地加重了全球疾病负担。在韩国,截至 2022 年,19 岁及以上人群的糖尿病患病率为 12.5%,30 岁及以上人群的患病率为 14.8%。据估计,19 岁及以上的糖尿病患者总数为 540 万人。糖尿病发病率从 2006 年的每千人 8.1 例降至 2014 年的每千人 6.3 例,之后又回升至 2019 年的每千人 7.5 例。与此同时,1 型糖尿病的发病率大幅上升,从 1995 年的每 10 万人 1.1 例上升到 2016 年的每 10 万人 4.8 例,2017 年的发病率达到每 10 万人 41.0 例。此外,妊娠糖尿病的患病率也从 2007 年的 4.1%大幅上升到 2023 年的 22.3%。这些变化导致糖尿病的总医疗费用增加,包括门诊和住院服务费用。因此,迫切需要有效的糖尿病预防战略。
{"title":"Changes in the Epidemiological Landscape of Diabetes in South Korea: Trends in Prevalence, Incidence, and Healthcare Expenditures.","authors":"Kyoung Hwa Ha, Dae Jung Kim","doi":"10.3803/EnM.2024.2073","DOIUrl":"10.3803/EnM.2024.2073","url":null,"abstract":"<p><p>Diabetes is a serious public health concern that significantly contributes to the global burden of disease. In Korea, the prevalence of diabetes is 12.5% among individuals aged 19 and older, and 14.8% among individuals aged 30 and older as of 2022. The total number of people with diabetes among those aged 19 and older is estimated to be 5.4 million. The incidence of diabetes decreased from 8.1 per 1,000 persons in 2006 to 6.3 per 1,000 persons in 2014, before rising again to 7.5 per 1,000 persons in 2019. Meanwhile, the incidence of type 1 diabetes increased significantly, from 1.1 per 100,000 persons in 1995 to 4.8 per 100,000 persons in 2016, with the prevalence reaching 41.0 per 100,000 persons in 2017. Additionally, the prevalence of gestational diabetes saw a substantial rise from 4.1% in 2007 to 22.3% in 2023. These changes have resulted in increases in the total medical costs for diabetes, covering both outpatient and inpatient services. Therefore, effective diabetes prevention strategies are urgently needed.</p>","PeriodicalId":11636,"journal":{"name":"Endocrinology and Metabolism","volume":" ","pages":"669-677"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Importance of the Hemoglobin Glycation Index for Risk of Cardiovascular and Microvascular Complications and Mortality in Individuals with Type 2 Diabetes. 血红蛋白糖化指数对 2 型糖尿病患者心血管和微血管并发症及死亡率风险的重要性。
IF 3.9 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-01 Epub Date: 2024-10-15 DOI: 10.3803/EnM.2024.2001
Claudia Regina Lopes Cardoso, Nathalie Carvalho Leite, Gil Fernando Salles

Backgruound: This study investigated the prognostic importance of the hemoglobin glycation index (HGI) for macrovascular and microvascular outcomes, mortality, and hypoglycemia occurrence in a type 2 diabetes cohort and compared it to glycated hemoglobin (HbA1c).

Methods: Baseline and mean first-year HGI and HbA1c, and the variability thereof, were assessed in 687 individuals with type 2 diabetes (median follow-up, 10.6 years). Multivariable Cox regression was conducted to evaluate the associations of HGI and HbA1c parameters with macrovascular (total and major cardiovascular events) and microvascular outcomes (microalbuminuria, advanced renal failure, retinopathy, and peripheral neuropathy), mortality (all-cause and cardiovascular), and moderate/severe hypoglycemia occurrence.

Results: During follow-up, there were 215 total cardiovascular events (176 major) and 269 all-cause deaths (131 cardiovascular). Microalbuminuria developed in 126 patients, renal failure in 104, retinopathy in 161, and neuropathy in 177. There were 90 hypoglycemia episodes. Both HGI and HbA1c predicted all adverse outcomes, except microalbuminuria and hypoglycemia. Their adjusted risks were roughly equivalent for all outcomes. For example, the adjusted hazard ratios (HRs) with 95% confidence intervals (CIs), estimated for 1 standard deviation increments, of mean first-year HGI were 1.23 (1.05 to 1.44), 1.20 (1.03 to 1.38), 1.36 (1.11 to 1.67), 1.28 (1.09 to 1.67), and 1.29 (1.09 to 1.54), respectively, for cardiovascular events, all-cause mortality, renal failure, retinopathy, and neuropathy; whereas the respective HRs (95% CIs) of mean HbA1c were 1.31 (1.12 to 1.53), 1.28 (1.11 to 1.48), 1.36 (1.11 to 1.67), 1.33 (1.14 to 1.55), and 1.29 (1.09 to 1.53).

Conclusion: HGI was no better than HbA1c as a predictor of adverse outcomes in individuals with type 2 diabetes, and its clinical use cannot be currently advised.

研究背景本研究调查了血红蛋白糖化指数(HGI)对 2 型糖尿病队列中大血管和微血管结局、死亡率和低血糖发生率的预后重要性,并将其与糖化血红蛋白(HbA1c)进行了比较:方法: 对 687 名 2 型糖尿病患者(中位数随访 10.6 年)的基线和第一年平均 HGI 和 HbA1c 及其变异性进行了评估。采用多变量 Cox 回归评估 HGI 和 HbA1c 参数与大血管(总和主要心血管事件)和微血管结局(微量白蛋白尿、晚期肾衰竭、视网膜病变和周围神经病变)、死亡率(全因和心血管)以及中度/严重低血糖发生率的关系:在随访期间,共发生了 215 起心血管事件(176 起主要事件)和 269 起全因死亡事件(131 起心血管事件)。126名患者出现微量白蛋白尿,104名出现肾功能衰竭,161名出现视网膜病变,177名出现神经病变。共发生 90 次低血糖。除微量白蛋白尿和低血糖外,HGI 和 HbA1c 均可预测所有不良后果。它们对所有结果的调整风险大致相同。例如,第一年平均 HGI 的调整后危险比 (HRs) 及 95% 置信区间 (CIs)(按 1 个标准差增量估算)分别为 1.23(1.05 至 1.44)、1.20(1.03 至 1.38)、1.36(1.11 至 1.67)、1.28(1.09 至 1.67)和 1.29(1.09 至 1.54)。而平均 HbA1c 的 HRs(95% CIs)分别为 1.31(1.12 至 1.53)、1.28(1.11 至 1.48)、1.36(1.11 至 1.67)、1.33(1.14 至 1.55)和 1.29(1.09 至 1.53):在预测 2 型糖尿病患者的不良后果方面,HGI 不比 HbA1c 更好,目前还不能建议临床使用 HGI。
{"title":"Importance of the Hemoglobin Glycation Index for Risk of Cardiovascular and Microvascular Complications and Mortality in Individuals with Type 2 Diabetes.","authors":"Claudia Regina Lopes Cardoso, Nathalie Carvalho Leite, Gil Fernando Salles","doi":"10.3803/EnM.2024.2001","DOIUrl":"10.3803/EnM.2024.2001","url":null,"abstract":"<p><strong>Backgruound: </strong>This study investigated the prognostic importance of the hemoglobin glycation index (HGI) for macrovascular and microvascular outcomes, mortality, and hypoglycemia occurrence in a type 2 diabetes cohort and compared it to glycated hemoglobin (HbA1c).</p><p><strong>Methods: </strong>Baseline and mean first-year HGI and HbA1c, and the variability thereof, were assessed in 687 individuals with type 2 diabetes (median follow-up, 10.6 years). Multivariable Cox regression was conducted to evaluate the associations of HGI and HbA1c parameters with macrovascular (total and major cardiovascular events) and microvascular outcomes (microalbuminuria, advanced renal failure, retinopathy, and peripheral neuropathy), mortality (all-cause and cardiovascular), and moderate/severe hypoglycemia occurrence.</p><p><strong>Results: </strong>During follow-up, there were 215 total cardiovascular events (176 major) and 269 all-cause deaths (131 cardiovascular). Microalbuminuria developed in 126 patients, renal failure in 104, retinopathy in 161, and neuropathy in 177. There were 90 hypoglycemia episodes. Both HGI and HbA1c predicted all adverse outcomes, except microalbuminuria and hypoglycemia. Their adjusted risks were roughly equivalent for all outcomes. For example, the adjusted hazard ratios (HRs) with 95% confidence intervals (CIs), estimated for 1 standard deviation increments, of mean first-year HGI were 1.23 (1.05 to 1.44), 1.20 (1.03 to 1.38), 1.36 (1.11 to 1.67), 1.28 (1.09 to 1.67), and 1.29 (1.09 to 1.54), respectively, for cardiovascular events, all-cause mortality, renal failure, retinopathy, and neuropathy; whereas the respective HRs (95% CIs) of mean HbA1c were 1.31 (1.12 to 1.53), 1.28 (1.11 to 1.48), 1.36 (1.11 to 1.67), 1.33 (1.14 to 1.55), and 1.29 (1.09 to 1.53).</p><p><strong>Conclusion: </strong>HGI was no better than HbA1c as a predictor of adverse outcomes in individuals with type 2 diabetes, and its clinical use cannot be currently advised.</p>","PeriodicalId":11636,"journal":{"name":"Endocrinology and Metabolism","volume":" ","pages":"732-747"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525700/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Amelioration of Insulin Resistance after Delivery Is Associated with Reduced Risk of Postpartum Diabetes in Women with Gestational Diabetes Mellitus. 产后胰岛素抵抗的改善与妊娠糖尿病妇女产后糖尿病风险的降低有关。
IF 3.9 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-01 Epub Date: 2024-08-21 DOI: 10.3803/EnM.2024.1974
Heejun Son, Joon Ho Moon, Sung Hee Choi, Nam H Cho, Soo Heon Kwak, Hak Chul Jang

Backgruound: Identifying risk factors for postpartum type 2 diabetes in women with gestational diabetes mellitus (GDM) is crucial for effective interventions. We examined whether changes in insulin sensitivity after delivery affects the risk of type 2 diabetes in women with GDM.

Methods: This prospective cohort study included 347 women with GDM or gestational impaired glucose tolerance, who attended the follow-up visits at 2 months postpartum and annually thereafter. Changes in insulin sensitivity were calculated using the Matsuda index at GDM diagnosis and at 2 months postpartum (ΔMatsuda index). After excluding women with pregestational diabetes or those followed up only once, we analyzed the risk of postpartum type 2 diabetes based on the ΔMatsuda index tertiles.

Results: The incidence of type 2 diabetes at the two-month postpartum visit decreased with increasing ΔMatsuda index tertiles (16.4%, 9.5%, and 1.8%, P=0.001). During a 4.1-year follow-up, 26 out of 230 women who attended more than two follow-up visits (11.3%) developed type 2 diabetes. Compared to the lowest tertile, subjects in the highest ΔMatsuda index tertile showed a significantly reduced risk of type 2 diabetes (hazard ratio, 0.33; 95% confidence interval, 0.12 to 0.93; P=0.036) after adjusting for confounders.

Conclusion: Improvement in insulin sensitivity after delivery is associated with a reduced risk of postpartum type 2 diabetes in women with GDM. Postpartum changes in insulin sensitivity could be a useful prediction for future type 2 diabetes development in women with GDM.

背景:确定妊娠糖尿病(GDM)妇女产后患 2 型糖尿病的风险因素对于有效干预至关重要。我们研究了产后胰岛素敏感性的变化是否会影响妊娠糖尿病妇女罹患 2 型糖尿病的风险:这项前瞻性队列研究纳入了 347 名患有 GDM 或妊娠期糖耐量受损的妇女,她们在产后 2 个月接受了随访,此后每年随访一次。胰岛素敏感性的变化是通过 GDM 诊断时和产后 2 个月时的松田指数(Δ松田指数)计算得出的。在排除妊娠前糖尿病妇女或仅随访过一次的妇女后,我们根据ΔMatsuda指数三等分法分析了产后2型糖尿病的风险:结果:产后两个月随访时的 2 型糖尿病发病率随着 ΔMatsuda 指数三分位数的增加而降低(16.4%、9.5% 和 1.8%,P=0.001)。在为期 4.1 年的随访中,230 名接受过两次以上随访的妇女中有 26 人(11.3%)患上了 2 型糖尿病。与最低三分位数相比,在调整了混杂因素后,ΔMatsuda指数最高三分位数的受试者罹患2型糖尿病的风险显著降低(危险比为0.33;95%置信区间为0.12至0.93;P=0.036):结论:产后胰岛素敏感性的改善与 GDM 妇女产后罹患 2 型糖尿病的风险降低有关。产后胰岛素敏感性的变化可以有效预测 GDM 妇女未来 2 型糖尿病的发展。
{"title":"Amelioration of Insulin Resistance after Delivery Is Associated with Reduced Risk of Postpartum Diabetes in Women with Gestational Diabetes Mellitus.","authors":"Heejun Son, Joon Ho Moon, Sung Hee Choi, Nam H Cho, Soo Heon Kwak, Hak Chul Jang","doi":"10.3803/EnM.2024.1974","DOIUrl":"10.3803/EnM.2024.1974","url":null,"abstract":"<p><strong>Backgruound: </strong>Identifying risk factors for postpartum type 2 diabetes in women with gestational diabetes mellitus (GDM) is crucial for effective interventions. We examined whether changes in insulin sensitivity after delivery affects the risk of type 2 diabetes in women with GDM.</p><p><strong>Methods: </strong>This prospective cohort study included 347 women with GDM or gestational impaired glucose tolerance, who attended the follow-up visits at 2 months postpartum and annually thereafter. Changes in insulin sensitivity were calculated using the Matsuda index at GDM diagnosis and at 2 months postpartum (ΔMatsuda index). After excluding women with pregestational diabetes or those followed up only once, we analyzed the risk of postpartum type 2 diabetes based on the ΔMatsuda index tertiles.</p><p><strong>Results: </strong>The incidence of type 2 diabetes at the two-month postpartum visit decreased with increasing ΔMatsuda index tertiles (16.4%, 9.5%, and 1.8%, P=0.001). During a 4.1-year follow-up, 26 out of 230 women who attended more than two follow-up visits (11.3%) developed type 2 diabetes. Compared to the lowest tertile, subjects in the highest ΔMatsuda index tertile showed a significantly reduced risk of type 2 diabetes (hazard ratio, 0.33; 95% confidence interval, 0.12 to 0.93; P=0.036) after adjusting for confounders.</p><p><strong>Conclusion: </strong>Improvement in insulin sensitivity after delivery is associated with a reduced risk of postpartum type 2 diabetes in women with GDM. Postpartum changes in insulin sensitivity could be a useful prediction for future type 2 diabetes development in women with GDM.</p>","PeriodicalId":11636,"journal":{"name":"Endocrinology and Metabolism","volume":" ","pages":"701-710"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142008518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insulin-Like Growth Factor 1 as a Pillar in Acromegaly: From Diagnosis to Long-Term Management. 胰岛素样生长因子 1 是肢端肥大症的支柱:从诊断到长期管理。
IF 3.9 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-01 Epub Date: 2024-08-21 DOI: 10.3803/EnM.2024.2096
Mi Kyung Kim
{"title":"Insulin-Like Growth Factor 1 as a Pillar in Acromegaly: From Diagnosis to Long-Term Management.","authors":"Mi Kyung Kim","doi":"10.3803/EnM.2024.2096","DOIUrl":"10.3803/EnM.2024.2096","url":null,"abstract":"","PeriodicalId":11636,"journal":{"name":"Endocrinology and Metabolism","volume":" ","pages":"693-695"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Endocrinology and Metabolism
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1